Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin combination therapy versus metformin-, acarbose-, or gliclazide MR-based combinations in drug-naive type 2 diabetes
ChiCTR-IPR-14005716Phase 4Recruiting
- Sponsor
- China-Japan Friendship Hospital
- Start
- Dec 2014
- Modality
- Small Molecules, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + metformin, Saxagliptin + acarbose and Saxagliptin + gliclazide MR (3 arms). Primary endpoint: Absolute change in HbA1c from baseline to week 24. Started Dec 2014; status: recruiting.
02
Drugs
saxagliptinmetforminacarbosegliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-14005716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005716.